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International Society for Stem Cell Research 2011,
ninth annual meeting in Toronto (June 15eJune 18,
2011)The International Society for Stem Cell Research ninth
annual meeting in 2011 was held in Toronto, Canada. The
meeting began within an earnest welcome by the presi-
dent, Elaine Fuchs. The initial session was named “Past,
Present, and Future” to showcase a historical perspective
of stem cell research, and then presented information on
how to implement stem cell based therapeutic strategies
in humans. The marketing of stem cell therapies before
their safety and efficacy have been demonstrated is an
ongoing issue. Irving Weissman (Stanford University School
of Medicine, USA) emphasized the importance of clear
nomenclature in establishing the definition of any partic-
ular adult stem cell line. Single-cell clonality in conjunction
with transplantation, as employed in the hematopoietic
stem cell (HSC) field, he argued, is absolutely required for
a rigorous definition of stem cells. He laid out a set of
criteria that should be in place before marketing proceeds:
(1) preclinical proof of principle; (2) verification of data in
independent laboratories; (3) review by involvement of
a medical ethics committee to protect the rights of human
donors and their samples; and (4) approval by an official
regulatory body such as the U.S. Food and Drug Adminis-
tration (FDA).
Germline stem cells
Ruth Lehman (New York University of School of Medicine,
USA; Curr. Biol. 21, 1373-1379, 2011) discussed Piwi-
interacting (pi) RNAs, which colocalize with H3K9me3
epigenetic marks at piRNA loci and showed how repression is
conserved in the restriction of germ cell fate. Azim Surani
(University of Cambridge, UK; Cell Stem Cell 4, 493-498,
2011) discussed a parallel model of reprogramming, namely
reversion of epiblast stem cells to an embryonic stem cell
(ESC)-like state. Two rounds of reprogramming occur in
normal development: (1) just after fertilization; and (2) at
embryonic Day 7.25 in mice. This seems to give a restriction1607-551X/$36
doi:10.1016/j.kjms.2012.02.020rule for germline stem cells. An analogous reprogramming
model was presented by Hans Scho¨ler (Max Plank Institute
for Molecular Biomedicine, Germany; Nat. Cell Biol. 13, 66-
71, 2011). He discussed the reprogramming of postnatal
somatic and germ cells, epiblast stem cells, and the utility of
cell culture to ‘lock’ the epigenetic state of cells. He
emphasized the critical role of endothelial cells in this area.
Owen Tamplin (Zon Laboratory, Children’s Hospital Boston,
USA) presented the critical role of the sphingosine-1-
phosphate receptor pathway in HSCs. This interferes with
lipid signaling to determine the fate of HSCs in the vascu-
lature before they migrate to the caudal hematopoietic
tissues. Elaine Dzierzak (Erasmus Medical Center, The
Netherlands; Blood, 117, 6132-6134, 2011; Blood, 117, 5088-
5091, 2011) reviewed hematopoiesis, including the devel-
opment of the first HSCs from the aorta-gonad-mesonephros
(AGM) region. CD41 is present on both the AGM and yolk sac
HSCs. Sean Morrison (University of Michigan, Ann Arbor, USA)
reviewed the complexity of the HSC niche in adults,
comprising a multicellular environment with potentially
overlapping contributors from different cell types. HSCs
residing in perivascular stromal cells secrete stem cell factor
(SCF) for their own maintenance. This is the first genetic
study of a key niche factor that promotes the maintenance
of stem cells in the hematopoietic system. Margaret Good-
ells (Baylor College of Medicine, USA) reported that the loss
of DNA methyltransferase in HSCs results in impairment of
differentiation. Shosei Yoshida (National Institute for Basic
Biology, Japan) described syncytial spermatogonia in mice
and showed that spermatogonia are more dynamic and can
revert or dedifferentiate to a stem cell state. Emi Nishimura
(Tokyo Medical and Dental University, Japan; Cell Stem Cell
8, 177-187, 2011) presented the concept that tissue stem
cells can themselves create the niche for other stem cell
types, in which collagen XVII gene expression by hair follicle
stem cells is required for the maintenance of adjacent
melanocyte stem cells by providing TGFb signaling.
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cell divisions
Scott Williams (Fuchs Laboratory, Rockefeller University,
USA; Nature 470, 353-358, 2011) studied the regulation of
switching between symmetric and asymmetric cell divisions
during the construction of mammalian skin. Lentivirus
shRNA, which is used to disrupt the gene that controls
asymmetric cell division, caused functional defects in skin
differentiation leading to hyperpermeability and skin thin-
ning though aberrant loss of Notch signaling. Hans Clevers
(Hubrecht Institute, The Netherlands; Cell 145, 851-862,
2011; Nature 476, 293-297, 2011) showed that adult stem
cells are not all alike. He demonstrated that intestinal stem
cells undergo symmetric divisions followed by the stochastic
determination of daughter stem cells. Each crypt unit
becomes monoclonal on a random basis, consistent with the
model of neutral competition between stem cells. R-Spondin
1-mediated Wnt signaling is a critical downstream pathway
for the differentiation of Lgr4/5-intestinal stem cells. Pier
Paole di Fiore (Instituto FIRC di Oncologia, Molecolare,
University of Genoa, Italy; Biochim. Biophys. Acta 1815, 26-
43, 2011) discussed that the stem cell-like fraction of
mammary tumors was shown to revert to a pattern of
predominantly symmetric cell division. This was caused by
the loss of p53 gene expression, as shown by partitioning of
NUMB to both daughter cells using a vital staining. John Dick
(University Health Network, Canada; Science 333, 218-221,
2011; Nature 469, 362-367, 2011) reported two important
findings. First, the identification and profiling of single-cell
clones of functionally pure human HSCs and second, how to
model the clonal diversity of cancer stem cells in leukemia.
CD49f is expressed in human HSCs and the authors achieved
long-term multilineage engraftment of single human cells in
immunocompetent mice, using Thy1þ Rodamine 123lo
CD49fþ cells. Loss of CDKN2A/B was associated with
increased aggressiveness and competitiveness of leukemia-
initiating cells. Alysson Muotri (University of California, San
Diego, USA; Cell 143, 527-539, 2010) found on de novo L1
retrotransposon insertions in induced pluripotent stem cells
(iPSCs)-derived neurons from patients with Rett syndrome
and autism spectrum disorders. The study of somatic
mosaicism is highly relevant to the future of iPSC-based
therapy. Athurva Gore (University of California, San Diego,
USA) and Uri Ben-David (The Hebrew University, Israel; Cell
Stem Cell 7, 521-531, 2010) described studies on the genetic
variation and karyotype abnormalities that arise as
a consensus of selection and cloning of primary cells in
culture and also on the generation of iPSCs.
Aging
Irina Conboy (University of California, Berkeley, USA; Aging
3, 556-563, 2011) hypothesized that muscle stem cells
remain young while the surrounding niche ages. Amy
Wagners (Harvard University, USA) also described cultured
satellite muscle cells as potential tools for discovery of new
bioactive molecules for treating muscle diseases. Michael
Rudnicki (Ottawa Hospital Research Institute, Canada) dis-
cussed the biochemical modulation of transcription factors
in muscle satellite cell differentiation.Genomic reprogramming
Takayuki Tanaka (Kyoto University, Japan) found that
a substantial fraction of cases of chronic infantile neuro-
logical cutaneous and articular syndrome are caused by
somatic mosaic NLRP3 mutations, leading to both cell-
autonomous and non-cell autonomous macrophage-
dependent effects in a dominant manner. Shinya Yama-
naka (Kyoto University, Japan; Nature 474, 225-229, 2011)
presented the efficient application of nuclear reprogram-
ming technology in embryos for avoiding mutation. He has
discovered that Glis1 compensates very effectively for the
use of c-Myc to generate iPSCs without causing oncogenic
side effects. He also demonstrated that the inconsistent
data of iPSCs with ESC reported by other researchers are
associated with the higher ‘stemness’ quality and pluri-
potency of iPSCs.
Clinical application
Some of the most exciting progress continued to be in the
development of new therapies for those suffering from
disease- or injury-related blindness. Michele De Luca
(University of Milan, Italy; N. Engl. J. Med. 363, 147-153,
2010) described progress in delivering autologous limbal
cells implanted surgically implanted back into the patient’s
damaged eye. In more than 75% of cases, corneal regener-
ation was restored and was stable for long as 10 years,
attributed to p63þ holoclones observed in the limbal
outgrowths. A promising application of human ESCs is in the
treatment of macular degeneration. Peter Coffey (Univer-
sity College London, UK) reported the progress of a therapy
for macular degeneration by transplanting human ESC-
derived pigmented retinal epithelial cells. Peter Zandstra
(University of Toronto, Canada) described the large-scale
culture of pluripotent stem cells in suspension: differenti-
ating as ‘in-line’ for ready use. Christopher Breuer (Yale
University School of Medicine, USA) described early clinical
trials of a tissue-engineered vascular graft for the treatment
of congenital heart defects. He identified macrophages as
both the culprit in stenosis, a complication seen in a number
of patients, and as the driver of neovessel formation. This
result suggests the possibility of therapeutic approach using
a cell-free biomimetic scaffold to enhance innate regener-
ative mechanisms while minimizing the risk of occlusion.
Deserved recognition and parting thoughts
Richard Young (Massachusetts Institute of Technology, USA;
Cell 144, 940-954, 2011) and Stuart Orkin (Children’s
Hospital Boston, USA; Cell 145, 835-850, 2011) presented
the identification of mechanisms that regulate the switch
for self-renewal and differentiation in pluripotent stem
cells. Judy Lieberman (Harvard Medical School, USA)
conveyed the results of a recent genome-wide siRNA
screening and identified the inhibitors of breast-cancer-
tumor-initiating cells, in breast cancers.
The 2011 Outstanding Young Investigator award was
presented to Robert Blelloch (University of California, San
Francisco, USA; Nature 463, 621-626, 2010), who screened
the microRNAs (miRNAs) that influence self-renewal and
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that the opposing miRNA families (ESCs and let-7 miRNAs)
caused reprogramming in human iPSCs by influencing
pathways related to the mesenchymal-to-epithelial cell
transition (MET). The McEwen Centre Award for innovation
was given to Takahasi and Yamanaka. The Anne McLaren
Memorial Lecture was given by Nicole Le Douarin (Acade´mie
Des Sciences, Paris, France), who studied neural crest
function using quail/chicken chimeras.
Conclusion
This meeting in 2011 gave the impression that the field of
stem cell research is maturing rapidly and is increasing the
rate of development of clinical applications for novel stem
cell treatments. We are sure to hear more about how stemcell research is changing the face of science, increasing our
understanding of disease, and prompting the development
of new therapies.
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